Insilico Medicine tour between London and Dubai: Automation of drug labs reshapes assessment of biotech platforms
Listen to this article
Read by Anchor
The executive leadership of biotech company Insilico Medicine, listed on the Hong Kong Stock Exchange under 03696.HK since the end of 2025, will travel to London and Dubai for investment and technology meetings in November 2026 to showcase the latest developments in AI-driven therapies and laboratory automation. These engagements highlight the ongoing structural shift from traditional drug-development methods to automated, repeatable discovery platforms designed to address unmet medical needs and support healthy-longevity research, placing the Gulf region at the centre of the international debate on integrating generative algorithms into pharmaceutical research pipelines.
The European itinerary begins in London with the participation of the company’s founder and CEO, Dr. Alex Zavoronkov, at the Global Healthcare Jeffries 2026 conference held at The Waldorf Hilton from 16 to 19 November. The event, in its seventeenth edition, is the largest European investment gathering dedicated to the healthcare sector, attracting more than 4,100 participants representing over 800 public and private health organisations across biotech, pharma, devices and medical services. The conference serves as the flagship event of London’s Life Sciences Week, coordinating more than 15,000 scheduled meetings, including 9,500 one-on-one sessions that bring institutional investors together with executive teams to assess health-market opportunities. Zavoronkov will deliver a keynote address and take part in a panel on Chinese biotech on 18 November to review innovation dynamics and translational research.
The pivotal point in the investment appraisal, which Zavoronkov raises in the opening session of the UBS Global Biopharma Conference at the Rosewood London, lies in dismantling the sector’s traditional valuation metrics.While prevailing valuations have remained tied to clinical-development milestones and peak-revenue forecasts for a single drug molecule, the platform proposes a model that derives its core corporate value from the systemic AI capability to generate repeated, sequential therapeutic production lines rather than relying on an isolated molecule. The conference, organised by UBS on 16 and 17 November, brings together company leaders and institutional capital providers to discuss funding allocation strategies and cross-border partnerships, with a focus on Chinese biotech assets and their international expansion context.
The technical dialogue then moves directly to the region through the Dubai Future Week hosted by the Dubai Future Foundation from 18 to 21 November 2026 at the Emirates Towers and the Museum of the Future under the theme “For the Human of the Future”. The event gathers more than 10,000 participants across 75 sessions that combine the Dubai Future Forum and Dubai AI Week. Dr. Alex Aliber, co-founder and president of the company, is scheduled to deliver a keynote on the morning of 20 November titled “Generative AI and Laboratory Automation for Drug Discovery and Healthy Longevity”, outlining a closed-loop operational architecture that couples generative algorithms with fully automated robotic labs.
This integration of generative models with automated labs enables the bypass of historic bottlenecks in R&D, progressing from defining anti-aging targets to accelerating the production of candidate compounds for trials.The company continues to deploy its Pharma.AI platform in therapeutic areas including fibrosis, oncology, immunology, pain management and metabolic disorders, while expanding into advanced materials, agriculture, nutrition and veterinary science, turning the platform from an isolated computational tool into an integrated drug-production system.
What This Means for the Region
The participation of Insilico Medicine’s leadership in Dubai alongside its investment tour in London carries practical implications for Gulf investment funds and research institutions, as the UAE and Saudi Arabia lead distinctive initiatives in healthy-longevity research and biotech. Showcasing the closed-loop robotic-lab architecture compels local investors to reset startup evaluation criteria, shifting from the traditional bet on a single therapeutic molecule with a slow clinical trajectory to investing in the efficiency of automated platforms that can repeatedly and sustainably lower the cost of exploring biological targets.
At the level of infrastructure and talent, adopting this pathway in Gulf and Egyptian research centres requires a shift in required competencies, moving the need from traditional wet-lab researchers to system-automation engineers and bio-informatics scientists capable of managing generative algorithms and integrated robotic systems. The acceleration in generating therapeutic candidates also places regional health-regulatory bodies before the need to update clinical-review and approval frameworks for products invented and tested through closed-loop algorithmic workflows.